Peregrine Pharmaceuticals adds Tarvacin trial site

By Jennifer Chiou

New York, Oct. 21 - Peregrine Pharmaceuticals, Inc. said The University of Texas M. D. Anderson Cancer Center began patient enrollment in an ongoing phase I clinical trial of Tarvacin Anti-Cancer.

"M.D. Anderson is one of the world's most prestigious cancer centers and we expect that their participation in this clinical trial will help expedite the study," chief executive officer Steven King said in a news release.

"Tarvacin shows promise in treating both cancers and viral infections and this study will enable us to further evaluate the drug's potential in refractory solid tumors."

It is the fourth clinical trial site testing the safety, tolerability and pharmacokinetics of Tarvacin in patients with advanced solid tumor malignancies who have not responded to available treatments. The open-label, dose-escalation study is for up to 28 patients.

Tarvacin is a monoclonal antibody that binds specifically to phospholipids, a basic component of the cell structure that is exposed only on the surface of tumor blood vessel cells.

Based in Tustin, Calif., Peregrine is a biopharmaceutical company focused on cancer and viral diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.